Crucible Therapeutics appoints new Chief Executive Officer
Crucible Therapeutics, a University of Sheffield spinout developing novel therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, has announced the appointment of Dr Cliff Holloway as its Chief Executive Officer.